Outcomes for patients with KMT2Ar ALL. (A) Intersection graph showing association between KMT2Ar, infant ALL diagnosis and lineage switch. (B) Flow diagram showing overall outcomes of patients with KMT2Ar ALL following CD19 CAR. ∗2 patients died of CAR toxicity; ^ˆ1 died of post-HSCT TRM. CR, complete remission; NE, nonevaluable; NR, nonresponse (including partial response, stable disease, and progressive disease). (C) Relapse phenotype of non-KMT2Ar patients. (D) Relapse phenotype of KMT2Ar patients. (E) Outcomes for individual patients with KMT2Ar ALL.